Medtronic stock falls 1.62 percent after raised FY27 guidance

Medtronic stock stood at USD 89.30 on the NYSE on September 23, 2026, down 1.62 percent from the prior close of USD 90.77. The move contrasts with a fiscal first quarter in which revenue and adjusted earnings exceeded consensus estimates.

Revenue beats consensus

Medtronic reported USD 9.756 billion in revenue for Q1 fiscal 2027, the quarter ended July 31, 2026. In its September 1, 2026 release, PR Newswire said revenue increased 13.7 percent on both a reported and organic basis.

The result was USD 206 million above the USD 9.55 billion consensus cited by Investing.com, a 2.16 percent beat. The comparison matters because it shows that the headline growth was accompanied by execution above the market baseline.

Guidance moves higher

GAAP diluted EPS was USD 1.14, while adjusted EPS reached USD 1.45 in Q1 fiscal 2027. Adjusted EPS exceeded the USD 1.39 consensus by USD 0.06, or 4.32 percent, according to Investing.com.

Medtronic also lifted its fiscal 2027 organic revenue growth outlook to 7.25 to 7.75 percent. The range represents a 50 basis point increase from the prior projection, making guidance the key test for whether the Q1 performance can extend beyond the extra selling week in the company fiscal calendar.

Stock trades below yearly high

Medtronic stock was USD 17.03 below its 52-week high of USD 106.33 on September 23, 2026, leaving the reference price 16.02 percent below that level. Its 52-week low was USD 73.31, so the stock remained USD 15.99 above the bottom of that period.

For investors, the central contrast is clear: Q1 revenue growth and adjusted EPS beat consensus, while the September 23 market snapshot still showed a negative 1.62 percent daily change. The next valuation debate will center on whether the 7.25 to 7.75 percent organic growth range can support a recovery toward the upper half of the yearly trading band.